On behalf of the Program in Evidence Based Care, the Disease Pathway Management program is pleased to announce that a new guideline, GL #4-18, Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma, is now available on Ontario Health (Cancer Care Ontario)’s website.

Clinicians involved in the treatment of patients with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma who have received first-line therapy with cytoreductive surgery and neoadjuvant or adjuvant therapy, including:

• Gynecologic oncologists

• Medical oncologists

• Radiation oncologists

• Gynecologists

• Primary care providers

• Genetic counsellors

• Medical geneticists

• Pathologists

For questions about this guideline, please contact Ontario Health (Cancer Care Ontario)’s Program in Evidence-Based Care at ccopgi@mcmaster.ca.